Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its ...
Biogen's stock has had a rough time over the past few months. In late July, not only did European regulators reject Biogen's treatment for Alzheimer's disease, the company and partner Sage ...